Table II.

 Seated Systolic and Diastolic BP (mm Hg) at Baseline and Week 52/ET by Dosing Regimen at Week 52/ET

regimen	AML 5 + OM 40, mg/d (n=525)	AML 10 + OM 40, mg/d (n=378)	AML 10 + OM 40 + HCTZ 12.5, mg/d (n=287)	AML 10 + OM 40 + HCTZ 25, mg/d (n=419)	Othera (n=63)	Total Cohort (N=1672)
Baselineb mean systolic/diastolic BP, mm Hg	157.6/100.3	160.7/101.1	165.5/102.2	172.9/103.2	160.7/100.3	163.6/101.5
Week 52/ET mean systolic/diastolic BP, mm Hg	127.6/81.0	130.9/82.4	130.7/81.0	136.8/83.4	126.2/79.4	131.2/81.9
Mean change from baseline, mm Hg	30.0/19.3	29.8/18.7	34.8/21.2	36.1/19.8	34.5/20.9	32.4/19.6

Abbreviations: AML, amlodipine; BP, blood pressure; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil. ^aOther includes the following nonstandard treatment regimens as the final dosage: OM 40 mg/d, HCTZ 25 mg/d, AML 5 mg/d, AML 10 mg/d + OM 20 mg/d, AML 2.5 mg/d + OM 20 mg/d, AML 5 mg/d + OM 20 mg/d, AML 5 mg/d + OM 20 mg/d + HCTZ 12.5 mg/d, AML 10 mg/d + OM 20 mg/d + HCTZ 12.5 mg/d, AML 2.5 mg/d + OM 40 mg/d + HCTZ 12.5 mg/d, AML 5 mg/d + OM 40 mg/d + HCTZ 12.5 mg/d, and AML 5 mg/d + OM 40 mg/d + HCTZ 25 mg/d. ^bBaseline BP refers to BP at the start of the randomized phase of the study and was defined as the average of the visit values from the randomization visit and the visit before the randomization visit.